PURA Reports First Revenue Toward $3 Million Forecast
April 18 2017 - 8:05AM
InvestorsHub NewsWire
Dallas, Texas – April 18,
2017 – Puration, Inc. (USOTC:
PURA) today announced the Company has filed its 2016
annual financial report. The report includes the first
revenue since the Company launched its cannabis extraction
operations. The Company has published a $3 million revenue forecast plan anticipated from
sales to be generated from its first cannabis infused beverage
contracts. The first beverages have been launched.
EVERx CBD Infused Bottled Sports Water and EVERx Alkaline
Bottles Sports Water were launched at Arnold Schwarzenegger’s
recent Annual Arnold Sports Festival. The EVERx Products will
again be featured as part of North American Cannabis Holdings’,
(USOTC:
USMJ) AmeriCanna Cafe restaurant launch at the
Southwest Cannabis Conference and Expo in Fort Worth, Texas later
this week. The first PURA sales realized just before year end
2016 making their way onto the 2016 financial report amounted to
$100,000.
PURA operates the NCM Biotech, Inc. patent for cannabis extraction
to produce the finest cannabis extracts for infusion into food and
beverages. NCM Biotech has licensed to PURA the right to
utilize NCM Biotech’s patented cannabis extraction process to
produce cannabis extracts for infusion into recreational, fitness
wellness, alternative medicine and beauty products. NCM
Biotech exclusively owns U.S. Patent No. 9,199,960 entitled “METHOD
AND APPARATUS FOR PROCESSING HERBACEOUS PLANT MATERIALS INCLUDING
THE CANNABIS PLANT.” The license of the process to PURA
is the first and only license NCM Biotech has executed.
To learn more about
Puration:
purationinc.com
Disclaimer/Safe Harbor: This news release contains forward-looking
statements within the meaning of the Securities Litigation Reform
Act. The statements reflect the Company's current views with
respect to future events that involve risks and uncertainties.
Among others, these risks include the expectation that any of the
companies mentioned herein will achieve significant sales, the
failure to meet schedule or performance requirements of the
companies’ contracts, the companies’ liquidity position, the
companies’ ability to obtain new contracts, the emergence of
competitors with greater financial resources and the impact of
competitive pricing. In the light of these uncertainties, the
forward-looking events referred to in this release might not occur.
These statements have not been evaluated by the Food and Drug
Administration. These products are not intended to diagnose, treat,
cure or prevent any disease.
Puration Contact:
Brian Shibley, CEO
info@purationinc.com
+1-214-937-9097
Puration (CE) (USOTC:PURA)
Historical Stock Chart
From Aug 2024 to Sep 2024
Puration (CE) (USOTC:PURA)
Historical Stock Chart
From Sep 2023 to Sep 2024